As of June 10, 2025, Epizyme Inc (EPZM) reports a ROE (Return on Equity) of 1213.85%.
ROE (Return on Equity) measures how well a company generates profits from shareholders' investments, indicating equity efficiency.
Historical Trend of Epizyme Inc's ROE (Return on Equity)
Over recent years, Epizyme Inc's ROE (Return on Equity) has shown significant volatility. The table below summarizes the historical values:
| Date | ROE (Return on Equity) |
|---|---|
| 2021-12-31 | 1213.85% |
| 2020-12-31 | -125.31% |
| 2019-12-31 | -51.43% |
| 2018-12-31 | -53.06% |
| 2017-12-31 | -57.06% |
This slight downward trend highlights how Epizyme Inc manages its efficiency in generating profits from shareholders' equity over time.
Comparing Epizyme Inc's ROE (Return on Equity) to Peers
To better understand Epizyme Inc's position, it's useful to compare its ROE (Return on Equity) against industry peers. Below are selected comparisons:
| Company | ROE (Return on Equity) |
|---|---|
| Epizyme Inc (EPZM) | 1213.85% |
| Inhibrx Inc (INBX) | 1259.38% |
| Mersana Therapeutics Inc (MRSN) | 727.65% |
| Aligos Therapeutics Inc (ALGS) | 452.87% |
| Clene Inc. (CLNN) | 444.85% |
| Abbvie Inc (ABBV) | 128.66% |
Compared to its competitors, Epizyme Inc's ROE (Return on Equity) is among the highest compared to peers, suggesting efficient use of shareholder equity to generate profits.